Is it time to consider oral vancomycin treatment for the management of pediatric inflammatory bowel disease irrespective of the presence of primary sclerosing cholangitis?

Key Points

• The aim is to assess the viability of using oral vancomycin for pediatric inflammatory bowel disease management, regardless of liver complications.
• Analysis of existing literature on oral vancomycin treatment efficacy.
• Comparison of treatment outcomes in children with and without primary sclerosing cholangitis.
• Indications that oral vancomycin may be beneficial in treating pediatric inflammatory bowel disease.
• Results suggest effective management across different patient conditions.

Abstract